Nasdaq:US$15.62 (-0.43) | HKEX:HK$24.68 (+0.08) | AIM:£2.36 (+0.11)
Search
Announcements
1
23456789101112131415161718
found Documents: 881
Announcements & Press Releases, Oncology / Immunology | 14 Jan 2026

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment — — Savolitinib and osimertinib combination approved in C
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 7 Jan 2026

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —   Hong Kong, Shanghai & Florham Park, NJ — Wednesday, January 7, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Na
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Jan 2026

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
Hong Kong, Shanghai & Florham Park, NJ — Monday, January 5, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the effi
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jan 2026

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2025

Total Voting Rights
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 31, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) hereby notifies the market that as at December 31, 2025, the issued share capital of HUTCHMED consi
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Dec 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 — — Savolitinib has the potential to become the first selective MET inhibitor in China for MET-ampli
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Dec 2025

Blocklisting Six Monthly Return
Hong Kong, Shanghai & Florham Park, NJ — Monday, December 29, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) announces the following blocklisting six monthly return:   1. Name
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 29 Dec 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
— NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison —   Hong Kong, Shanghai &a
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 17 Dec 2025

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process —   Hong Kong, Shanghai & Florham Park, NJ —   Wedn
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Dec 2025

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
Hong Kong, Shanghai & Florham Park, NJ — Monday, December 8, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Security Adminis
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Dec 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Nov 2025

Total Voting Rights
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 27 Nov 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Thursday, November 27, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Nov 2025

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 5, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SAFFRON, a global Phase III study of ORPATH
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Nov 2025

Monthly Return
HKEX Announcement (PDF)
Oncology / Immunology, Press Releases | 3 Nov 2025

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising precli
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Oct 2025

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
— First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — — Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit ant
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Oct 2025

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 21, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 15 Oct 2025

List of Directors and Their Roles and Functions
The Board of Directors of HUTCHMED (China) Limited comprises 9 Directors as follows: Chairman and Non-executive Director Dr Dan ELDAR Executive Directors Dr Weiguo SU (Chief Executive Officer* and Chief Scientific Officer) Mr CHENG Chig Fung
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 Oct 2025

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 14, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 Oct 2025

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
— The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies —   Hong Kong, Shanghai & Florham Park, NJ — Monday, Octob
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Oct 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 2 Oct 2025

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED wil
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Sep 2025

Total Voting Rights
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Sep 2025

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 —   Hong Kong, Shanghai & Florham Park, NJ —   Friday, September 12, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Sep 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
Hong Kong, Shanghai & Florham Park, NJ — Friday, September 5, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED wil
Read More
Announcements & Press Releases, Regulatory Notice | 1 Sep 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 25 Aug 2025

List of Directors and Their Roles and Functions
The Board of Directors of HUTCHMED (China) Limited comprises 9 Directors as follows: Chairman and Non-executive Director Dr Dan ELDAR Executive Directors Dr Weiguo SU (Chief Executive Officer* and Chief Scientific Officer) Mr CHENG Chig Fung
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Group, Regulatory Notice | 25 Aug 2025

HUTCHMED Announces Appointment of Acting Chief Executive Officer
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 25, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence f
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Interim Reports, Regulatory Notice | 22 Aug 2025

Interim Report 2025
Notification letter to non-registered shareholders and request form: Notice of Publication of 2025 Interim ReportNotification letter to registered shareholders and request form: Notice of Publication of 2025 Interim Report2025 Interim Report2025 Interim Report (Chinese version)
Announcements & Press Releases, Oncology / Immunology | 20 Aug 2025

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Hong Kong, Shanghai & Florham Park, NJ —  Wednesday, August 20, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHY
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 7 Aug 2025

HUTCHMED Reports 2025 Interim Results
— Indications expansion driving growth and ATTC platform enriching pipeline — — $455 million in net income attributable to HUTCHMED driven by non-core partial disposal —   Hong Kong, Shanghai & Florham Park, NJ — Thursday, A
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Aug 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jul 2025

HUTCHMED to Announce 2025 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 3, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will be announcing its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jul 2025

Update on Joint Corporate Brokers in London
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has appointed Deutsche Bank AG (trading as Deutsche Numis) as its joint Corporate Brok
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jul 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2025

Total Voting Rights
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2025

Blocklisting Six Monthly Return
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Jun 2025

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy — — The only all-oral combination treatment option for these patients — — Consisten
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 10 Jun 2025

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, June 10, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on June 9, 2025, it granted share options (“Share Options”) under the Share Option Scheme ad
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Jun 2025

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
Hong Kong, Shanghai & Florham Park, NJ — Thursday, June 5, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Appl
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jun 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 2 Jun 2025

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study —   — Webcast to be held at 8:30 am HKT on Tuesday, June 3 t
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 May 2025

Total Voting Rights
Hong Kong, Shanghai & Florham Park, NJ — Friday, May 30, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) hereby notifies the market that as at May 30, 2025, the issued share capital of HUTCHMED consisted of 871,6
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 May 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Friday, May 23, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitini
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 May 2025

List of Directors and Their Roles and Functions
The Board of Directors of HUTCHMED (China) Limited comprises 9 Directors as follows: Chairman and Non-executive Director Dr Dan ELDAR Executive Directors Dr Weiguo SU (Chief Executive Officer and Chief Scientific Officer) Mr CHENG Chig Fung,
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 13 May 2025

Annual General Meeting held on May 13, 2025 – Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 13, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual Gener
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 May 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 24 Apr 2025

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 24, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED incl
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 22 Apr 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 22, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savo
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
1
23456789101112131415161718